Kabra Drugs Ltd
₹17.39▲ +0.12 (+0.69%)
KABRADG·BSE·Healthcare
Market Cap
40.68 Cr
PE Ratio
8.32
Volume
34,406
Day High - Low
18.45 - 17.11
52W High-Low
35.52 - 17.00
₹17.39▲ +0.12 (+0.69%)
Market Cap40.68 Cr
PE Ratio8.32
Volume34,406
Day High - Low18.45 - 17.11
52W High-Low35.52 - 17.00
Kabra Drugs Ltd (KABRADG): company summary
The company's annual net profit swung from a loss of ₹1 crore to a profit of ₹5 crore, showing a dramatic improvement.
Kabra Drugs Ltd (KABRADG) is a micro-cap Healthcare company valued at ₹41 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Kabra Drugs Ltd last traded at ₹17.39, modestly up 0.69% on the day.
- Financial performance
- The company's annual net profit swung from a loss of ₹1 crore to a profit of ₹5 crore, showing a dramatic improvement. The latest quarter saw net profit jump from a loss of ₹0 crore to ₹2 crore, while revenue surged 546.4% to ₹46 crore, indicating strong growth in the most recent period.
- Valuation multiples
- The stock trades at 8.3 times earnings, a discount to the Healthcare median of 32.0, 1.61 times book value.
- Things to watch
- The stock is 51.4% below its 52-week high, which highlights a significant drop from recent peak levels. The company has no identified promoter, which is typical for a widely held entity but may limit strategic control.
- Where it stands
- The company has turned from a net loss to a profit of ₹5 crore annually, with the latest quarter showing a sharp rise in revenue and net profit. The stock's distance below its 52-week high stands at 51.4%.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
5.3/10
Weak
Fair Value
Sign in to see
ROE
16.75%
Strong
P/E
8.32x
Cheap
Debt / Equity
0.02
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
Day₹17.11
₹18.45
52W₹17.00
₹35.52
DocStoX take
Supported by growth (9.0) and valuation (8.5), but held back by momentum (0.0). Growth looks strong at 9.0, but that is offset by momentum at 0.0 and quality at 2.4. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence5.3
/10
Weak
Quality
Weak
ROE 16.7%
Valuation
Cheap
P/E 8.3×
Growth
Strong
Revenue +24.9% 10Y CAGR
Risk
Moderate
D/E 0.02
Momentum
Weak
2% of 52-week range
At a glance
Market Cap
₹41 Cr
52W High / Low
₹36 / ₹17
Dividend Yield
0.00%
Promoter Holding
0.00%
EPS (TTM)
₹2.09
Book Value
₹12.49
Key highlights
- Low leverage — D/E 0.02
- Undemanding at 8× earnings
- Revenue compounding 25% a year
- Loss-making in some of the last 5 years
- Quality is weak (2.4/10)
3 Positives4 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Kabra Drugs Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Kabra Drugs Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Related tools & concepts
Value Kabra Drugs Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing